Heyuan Biotech announced that the company held the 12th meeting of the fourth board of directors on October 9, 2026 to review and pass the bill to appoint Li Lin as the company's securities affairs representative. Li Lin will assist the board secretary in carrying out his work. The term of office will begin on the date of review and approval by the board of directors until the end of the fourth board of directors. Li Lin has obtained a certification for the qualification of the Secretary of the Board of Directors of the Science and Technology Innovation Board of the Shanghai Stock Exchange. Her qualifications have met the relevant regulations. She has not held shares in the company as of the date of disclosure of the announcement, and is unrelated to the relevant shareholders, directors and supervisors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.